Clonidine vs tizanidine for withdrawal syndrome

Phase 2

Recruiting

• Conditions: Opioid withdrawal syndrome.; Opioid dependence with withdrawal; F11.23

• Registration Number: IRCT20210213050348N1
• Lead Sponsor: Research Department of Alborz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

All the hospitalized patients in toxicology ICU in hospitals Kosar of Karaj and Loghman Hakim of Tehran who are addicted to opioids

Exclusion Criteria

No consent from patient's family

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Objective Opiate Withdrawal Scale (OOWS). Timepoint: Evaluating OOWS score in 6, 12, 24, 72 and 120 hours after hospitalization. Method of measurement: By using OOWS questionnaire.

Secondary Outcome Measures

Name	Time	Method
Sedation level. Timepoint: 6, 12, 24, 72 and 120 hours after hospitalization. Method of measurement: Recording level and content of consciousness.;Length of hospitalization. Timepoint: At the time of discharge. Method of measurement: Patient's charts.